Tuberculosis and Human Immunodeficiency Virus (HIV) Immune Reconstitution Syndrome Trial (THIRST)
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is twofold: (1) to assess the feasibility and safety of fixed dose
combination zidovudine/lamivudine/abacavir in HIV infected subjects with tuberculosis in a
resource-limited setting, and (2) to assess the impact of delayed versus early initiation
strategies for fixed dose combination zidovudine/lamivudine/abacavir on the rate of
tuberculosis-associated immune reconstitution inflammatory syndromes.
Phase:
Phase 4
Details
Lead Sponsor:
Duke University
Collaborators:
GlaxoSmithKline Kibongoto National Tuberculosis Hospital, Tanzania Kilimanjaro Christian Medical Centre, Tanzania